Mutations in RHBDF2 accelerate tumorigenesis by activating epidermal growth factor receptor (EGFR) signaling (Hosur et al., 2014) and are associated with tylosis esophageal cancer (Blaydon et al., 2012). Here, EGFR is linked to esophageal cancer.